Get started
Author

Svitlana Kulyk

Observed name: S. Kulyk
ORCID: 0000-0003-0346-3441
Observed ORCID: 0000-0003-0346-3441
OpenAlex ID: A5080913566
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
2023 · Lars D. Engstrom, Ruth Aranda, et al. · Cancer Discovery · 224
PDF
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers
2022 · Christopher R. Smith, Ruth Aranda, et al. · Journal of Medicinal Chemistry · 165
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
2022 · John M. Ketcham, Jacob Haling, et al. · Journal of Medicinal Chemistry · 96
PDF
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors
2022 · Christopher R. Smith, Ruth Aranda, et al. · Bioorganic & Medicinal Chemistry · 16
PDF
Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits
2022 · Christopher R. Smith, Svitlana Kulyk, et al. · RSC Medicinal Chemistry · 16
PDF
Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors
2021 · Christopher R. Smith, Svitlana Kulyk, et al. · Cancer Research · 14
Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition
2022 · Jonathan M. Maher, Rui Zhang, et al. · Toxicology and Applied Pharmacology · 13
PDF
198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009
2024 · A. Llombart Cussac, H.S. Rugo, et al. · ESMO Open · 7
PDF
Atropisomeric Racemization Kinetics of MRTX1719 Using Chiral Solvating Agent-Assisted 19F NMR Spectroscopy
2022 · Svitlana Kulyk, Susan M. De Paul, et al. · ACS Omega · 7
Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models
2021 · Christopher R. Smith, Lars D. Engstrom, et al. · Molecular Cancer Therapeutics · 2
Supplementary Figure S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S4 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S6 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Materials and Methods from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S6 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Materials and Methods from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S5 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S1 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S5 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Table S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Supplementary Figure S4 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · Lars D. Engstrom, Ruth Aranda, et al.
Works count: 62
Citation count: 558
H-index: 7
I10-index: 7
Year
Topic
Type